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Mijnheer de rector magnificus, geacht faculteitsbestuur, zeer 
gewaardeerde toehoorders. Ik geef deze lezing in het Engels.
Today I am honored to formally accept the title of professor 
and to share with you some of my academic inspirations, 
achievements, and future ambitions. Specifically, I will focus 
on those aspects of my research that relate to the molecular 
marvels that are antibiotics. I will begin by sharing some of 
my favorite tales of medical breakthroughs enabled by natural 
products up to and including the antibiotic era. I will also 
address the societal challenge we now face due to antibiotic 
resistance and how my research efforts aim to address this 
threat.
Gifts from Nature
When considering the various themes I might touch on 
to begin this lecture, I found myself bouncing a question 
around with friends and colleagues: what is the most valuable, 
naturally occurring, material?
The history and advancement of human civilization is 
intimately linked with our capacity to discover and use natural 
materials to our benefit. The ancient bronze and iron ages 
marked humanity’s ability to smelt raw metals and cast tools, 
instruments, and weapons that led to global expansion. Over 
the past millennia precious metals like gold and platinum, as 
well as gemstones like diamond and emerald, have risen to 
prominence and today are the most costly materials, by weight, 
to be stably found in nature.
It is the scarcity of these materials in Nature that makes them 
so valuable. In fact, it was the allure of transmuting cheaper, 
more abundant metals like lead and copper into the much 
rarer gold that drove the alchemists of the Middle Ages. While 
the practice of alchemy was ultimately abandoned during the 
Enlightenment, it did serve as the starting point for what we 
consider modern chemistry, including the field that I find most 
inspiring, organic chemistry. 
Organic chemistry is, generally speaking, concerned with the 
study of molecules that are associated with life - molecules 
often possessing what we call biological activity. The biological 
activity of organic molecules covers an array of possibilities 
ranging from their color, scent, and taste, to their ability to act 
as poisons or, in special cases, as medicines. 
The organic chemist is actually something of a modern day 
alchemist with the skills to transform inexpensive and readily 
available organic molecules into more complex compounds 
with new properties by means of what is called chemical 
synthesis. Over the past century synthetic organic chemistry 
has grown to be an incredibly powerful and useful branch 
of science. That said, the vast majority of (if not all) organic 
chemists agree, that the most impressive organic chemist of all 
time is, and continues to be, Mother Nature.
So, getting back to the question of the most valuable materials 
provided by Nature – are there naturally occurring, organic 
compounds that can rival precious metals and gems? 
Historically, the answer to this question is a resounding yes. 
Consider the economic forces that drove the Dutch “golden 
age” of the 17th century. It was largely the lucrative market for 
spices like pepper and nutmeg, that spawned the creation of 
the famous VOC, the Dutch East Indies Company. It is the 
biologically active organic compounds made by the producing 
plants that give these spices their desirable properties. Such 
spices were so sought after that in the early 1600s pepper was 
worth more by weight than gold, giving rise to the Dutch 
term, “peperduur”, an adjective still commonly used today to 
describe something very expensive. 
Many of you will also be aware that the Dutch were the first 
Europeans to settle the island of Manhattan, with the founding 
of a city aptly named New Amsterdam (which is of course 
today’s New York). In 1667 the Dutch swapped Manhattan 
with the British for a tiny volcanic island, in what is now part 
of Indonesia. This small island was one of a cluster of ten (the 
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other nine already owned by the Dutch) that were the only 
locations in the World where nutmeg could be grown. Nutmeg 
was at the time worth more than both pepper and gold. This 
island swap gave the Dutch a worldwide monopoly on Nutmeg 
production that lasted for many decades bringing vast wealth 
to cities like Leiden [1]. 
These examples of natural organic materials are, or were, 
financially valued due to their scarcity. I would argue however, 
that when it comes to Nature’s most important gifts to 
humanity, monetary worth is a rather poor gauge of real 
value. More to the point, none of the previously mentioned 
natural materials are medicines capable of preventing or 
curing disease. And so to focus the question, I would ask what 
naturally occurring substance has had the greatest impact on 
human health?
Considering the focus of much of my research is on 
antibiotics, I am naturally inclined to emphasize their 
importance. However, centuries prior to Fleming’s discovery 
of penicillin another naturally occurring “wonder drug” saved 
untold millions of lives while transforming our world. The 
antimalarial drug quinine is an organic compound produced 
by the Cinchona tree and can be extracted from the tree’s 
bark. In the 16th century, Jesuit missionaries in South America 
observed that the indigenous peoples of Peru and Bolivia 
drank a beverage prepared from the bark of the Cinchona tree 
to treat the symptoms of Malaria, most often severe fever. For 
this reason the Cinchona had become colloquially known as 
the “fever tree” by the locals [2]. 
By the early 19th century methods for the large scale isolation 
and purification of quinine from Cinchona bark were 
established in Europe. With ready access to the antimalarial 
drug in pure form the British Empire rapidly pushed its way 
into India and Africa. During this period British officers 
serving in these regions were provided a quinine ration 
that they were instructed to consume daily as an effective 
prophylaxis against malaria. There was one problem however: 
the incredibly bitter taste of quinine. In response, the officers 
found that by dissolving their daily dose of quinine in sugar-
flavored soda water mixed with gin, a much more palatable 
option was obtained and so was born the gin and tonic. 
Years later Winston Churchill would be quoted as saying 
“The gin and tonic has saved more Englishmen›s lives than 
all the doctors in the Empire.” It is also worth noting that the 
isolation of quinine from the Cinchona tree, and not chemical 
synthesis, remains the most effective means of producing the 
drug – Nature is an amazing organic chemist.
Perhaps not surprisingly, the Dutch also played an important 
role in quinine’s rise to prominence. By the mid 1800’s, the 
world’s supply of Cinchona bark was tightly controlled by 
the Peruvian government with exports to Europe exceeding 
six million pounds per year. To safeguard their interests, the 
Peruvians banned the export of cinchona seeds, creating an 
incentive for smugglers. However, in 1865 Englishman Charles 
Ledger succeeded in transporting several kilos of Cinchona 
seeds out of South America. When Ledger failed to secure 
a buyer for the seeds in England, he offered them to Dutch 
merchants who eagerly paid the asking price. These seeds 
were used to sow the first Cinchona plantations on the Dutch-
held Indonesian island of Java. The plants thrived in their 
new environment and by the early 1900s Dutch plantations 
were exporting 20 million pounds of Cinchona bark annually 
amounting to 97% of the world market [3]. The Dutch 
maintained this dominant position in the quinine world 
market until the Second World War. Under Nazi occupation at 
home and with the Japanese controlling Indonesia, the Dutch 
could not supply the allied forces with quinine. As a result tens 
of thousands of British and American soldiers are estimated to 
have died due to Malaria infections acquired in the African and 
Pacific theatres.
Quinine is generally credited as being the first natural product 
used to treat and prevent infectious disease. Quinine does not, 
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however, work against bacterial infections. For countries in the 
Northern hemisphere, Malaria is not a major concern given the 
equatorial habitat preferred by the Anopheles mosquito that 
transmits the disease. Rather, in Europe and North America 
bacterial infections were historically a much greater problem. 
The Antibiotic Era
For people born in the Netherlands in 1900, the average life 
expectancy was 46 years for men and 48 years for women. 
While today heart disease and cancer present the leading 
causes of death, 100 years ago, infectious disease was the 
biggest killer. At that time bacterial diseases like cholera, 
diphtheria, pneumonia, typhoid fever, plague, tuberculosis, 
typhus, syphilis were rampant, claiming the lives of young 
and old alike. This of course dramatically changed with the 
widespread introduction of antibiotics in the mid 1940s. 
With the availability of antibiotics, average life expectancies 
rose sharply in the 20th century and it is estimated that since 
its introduction more than 200 million lives have been saved 
thanks to penicillin alone. I think it’s safe to say that penicillin 
is one of Nature’s greatest gifts to mankind.
Many of you will be familiar with the story – the most 
common story - of the discovery of penicillin. As it goes, 
Scottish biologist Alexander Fleming discovered penicillin in 
1928 when he observed that a fungus, that had contaminated 
one of his experiments, appeared to excrete a compound 
that killed bacterial cells. As any good scientist does, Fleming 
wrote up his findings and submitted them for publication 
[4]. The potential impact of this discovery was not, however, 
immediately clear to the scientific community. Fleming’s 
findings would flounder in relative obscurity for more than 
a decade before Howard Florey and Ernst Chain, working at 
Oxford University, became the first to demonstrate penicillin’s 
capacity to cure bacterial infections in animals. With the 
outbreak of the Second World War, a massive collaborative 
research effort was then initiated with the goal of transforming 
penicillin from an academic curiosity to an anti-infective agent 
to support the allied forces. With financial backing from the 
governments of Great Britain and the United States as well as 
major drug companies including Merck, Pfizer, and Eli Lilly, 
the large-scale production of penicillin was realized. When the 
allies landed on the beaches at Normandy in 1944 they carried 
with them a million doses of penicillin, a significant advantage 
in the treatment of battlefield infections against the Germans 
who had not been successful in developing effective antibiotics. 
The Development of Penicillin in the Netherlands
This is the most commonly known historical account of the 
discovery and development of penicillin. There is however, 
another chapter in the story that unfolded much closer to 
where we stand today. In the Netherlands from 1943-1945, a 
covert operation saw a team of Dutch researchers succeed in 
secretly producing penicillin while under Nazi occupation. 
These efforts took place in the laboratories of the Nederlandsche 
Gist- en Spiritusfabriek, in English “The Netherlands Yeast and 
Alcohol Company”. Founded in 1869 by Jacques van Marken, a 
graduate from the TU Delft, this company was arguably one of 
the world’s first biotechnology companies, using fermentation-
based technologies to produce a range of products. By the early 
1900’s the company had become hugely successful and was 
one of Europe’s largest suppliers of the yeasts used in baking 
and brewing as well as a range of other products including the 
famous Dutch gin Jenever. 
Following the 1940 German occupation of the Netherlands, 
the Nazis saw the economic value in keeping this company 
operational. As such, employees were given “essential worker” 
status protecting them from forced labor in Germany. Also, 
as the story goes, they placed just a single guard to watch over 
the company’s day-to-day operations. This guard apparently 
had little interest in microbiology or fermentation technology 
but did have a definite appreciation for Jenever. Company 
management saw to it that his thirst was satisfied on a daily 
basis leaving the researchers inside the laboratories to pursue 
their interests uninterrupted [5]. 
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The head of the company’s research division at the time was 
Francois Gerard Waller and in early 1943, Waller and his team 
caught wind of the British and American effort to produce 
penicillin. By some accounts the Dutch scientists’ interest in 
penicillin had been sparked by information about the new 
wonder drug contained in the leaflets called De Vliegende 
Hollander (the Flying Dutchman) dropped by British pilots. 
Though completely cutoff from his colleagues in Britain and 
America, Waller decided that given his team’s world leading 
position in fermentation technology, they too would join the 
hunt for penicillin. 
While Allied researchers had the full support of the US 
and UK governments, the team in Delft had to work on a 
shoestring budget all the while keeping their efforts hidden 
from their occupiers. Starting in 1940 the Allies had imposed 
a strict embargo on the publication of any research relating 
to penicillin. As such Waller and his team had little to go on, 
relying primarily on Fleming’s original 1928 publication. In 
his seminal paper Fleming had noted that it was a strain of 
Penicillium mould that produced the antibiotic agent he later 
named penicillin. Notably, one key advantage that the Delft 
team had was proximity to the world’s most extensive fungal 
strain collection, the Centraalbureau for Schimmelculture (CBS) 
housed near Utrecht. 
In late 1943, Waller’s team contacted prof. Johanna Westerdijk, 
the curator of the CBS, and the first female professor in the 
Netherlands, with a request for any Penicillium strains in her 
collection. Professor Westerdijk responded by sending them 
twenty-one strains, six of which Waller’s team confirmed 
produced a substance capable of killing Staphylococcus aureus 
bacteria. The highest levels of antibiotic production were 
observed with a strain named Penicillium baculatum leading 
Waller to designate his team’s clandestine efforts as “project 
bacinol.” Waller rightly knew that the Nazis were also keenly 
interested in obtaining penicillin so a code name was essential 
to keeping his team’s work a secret. 
In the months that followed, the Delft team worked diligently to 
develop an effective procedure for the production of penicillin, 
which they continued to call bacinol. Limited access to 
infrastructure required resourcefulness - in fact, the first large 
scale fermentations of Penicillium baculatum where carried out 
in hundreds of empty milk bottles, the only available vessels by 
the summer of 1944. Working in complete isolation, Waller’s 
team devised their own optimal growth media and isolation 
protocols to achieve high production levels of their bacinol. 
By the end of 1944 they demonstrated that bacinol was also 
capable of clearing infections in mouse and rabbit models. 
Along with the liberation of the Netherlands on May 5, 1945 
came access to American made penicillin. A month later in 
June 1945 Waller and his colleagues excitedly confirmed that 
bacinol was in fact identical to penicillin. In the months that 
followed, the production of penicillin in Delft was scaled up. 
In November 1945, a mere 6 months following the liberation, 
21-year old Maria Geene became the first person to be treated 
with Dutch made penicillin and was completely cured within 
two weeks. In early 1946 clinical trials where conducted here 
at the Leiden Academic Hospital and by the end of that year 
penicillin was being widely used in Dutch hospitals. 
The fact that the Waller’s team had developed their own 
means of producing penicillin also had important intellectual 
property implications. Given that the Americans used a 
different strain of Penicillium and not Penicillium baculatum 
to produce their penicillin, there was no patent clash. The 
Nederlandsche Gist- en Spiritusfabriek, later renamed Gist-
Brocades, would go on to become one of the world’s largest 
producers of penicillin. 
The Golden Age and the Discovery Void
The discovery that a naturally-produced organic compound 
like penicillin could safely cure bacterial infections in humans 
ignited the hunt for other naturally occurring antibiotics. 
What followed was the “golden age” of antibiotic discovery, a 
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20-year period spanning the mid 1940s to mid 1960s, wherein 
the majority of the antibiotics that we still use today were 
found and brought to the clinic. 
Interestingly, most of the antibiotics discovered and developed 
in this period are produced by strains of bacteria isolated 
from soil samples. As it turns out, many soil dwelling bacteria 
produce the small organic molecules that we call antibiotics to 
limit the growth of other microorganisms competing for the 
same environment. Amazingly, the antibiotics found during 
the golden age of discovery work extremely well in treating 
infections inside a human body. This is a point that is worth 
emphasizing and a phenomenon that still amazes me. The 
bacteria that produce our clinically most important antibiotics 
did not evolve to live in human hosts. The fact that so many of 
the antibiotics that soil dwelling bacteria produce are able to 
function at all as medicines in a human body represents a huge 
stroke of luck for humankind. 
To put this good fortune into perspective it is worth 
considering just how challenging it is for researchers who work 
in the field of drug discovery to design new medicines that are 
not derived from natural products. The field of drug discovery 
is very much a numbers game where failure far exceeds success. 
It is estimated that the pharmaceutical industry produces only 
one new drug for every 10,000 novel organic compounds it 
generates [6]. The reasons for this high failure rate are many 
but are primarily attributable to efficacy and safety issues: 
some new drug candidates work well in artificial lab-based 
experiments that we refer to as “in vitro assays” but then 
fail to work in much more complex animal models, called 
“in vivo” assays. Even more frustrating, many experimental 
medicines can show great activity in both in vitro and in 
vivo animal studies but when it comes to human trials fail to 
show a beneficial effect or even worse, can be toxic. In this 
light it really is astonishing that so many naturally occurring 
antibiotics can be used directly as medicines – very much a 
case of nature delivering us a gift on a silver platter.
By the 1970s the general consensus was that all readily 
abundant, safe, and effective naturally-occurring antibiotics 
had been found. This so-called “low hanging fruit” was 
identified using systematic approaches for identifying 
antibacterial activity from diverse environments and samples. 
Furthermore, modern chemical and biochemical techniques 
became increasingly available with the power to elucidate 
the molecular structures and working mechanism of these 
important new drugs. 
With bacterial infections largely deemed to be under control 
thanks to a broad arsenal of new antibiotics, the focus of 
drug developers began to shift to other disease areas that 
had comparatively fewer therapeutic options - areas like 
cancer, heart disease, and neurodegenerative disease. Also, 
not unimportant, are the financial considerations that drove 
the decision making at large drug companies: with the low 
hanging fruit of naturally occurring antibiotics having been 
plucked in the previous decades, antibiotic discovery programs 
became increasingly challenging, offering a poorer return on 
investment. Simply put, other disease areas began to present 
more attractive business cases. The impact of these decisions 
are clear to see today: the past 50 years have witnessed 
amazing advancements in the development of innovative 
new medicines to treat heart disease and many cancers. By 
comparison, only three new classes of antibiotics have been 
brought to the clinic in the same time period. It boggles 
my mind to think that the vast majority of the antibiotics 
we still use today were discovered before I was born. The so 
called “discovery void” in antibiotic discovery is particularly 
worrisome in light of an issue I’m sure many of you will be 
familiar with: the emerging threat of antibiotic resistance.
Antibiotic Resistance
In the golden age of antibiotic discovery, deaths due to 
bacterial infections plummeted. Today, however, life-
threatening infections are on the rise as many bacteria are able 
to resist the action of antibiotics. Globally, each year 700,000 
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deaths are estimated to be due to infections with drug resistant 
bacteria – infections that might have been treatable in the 
1960s and 1970s before these strains became resistant. Even 
more worrisome are recent projections that suggest without 
serious investment and innovation in the field, by the year 
2050 antibiotic resistance may claim as many as 10 million 
lives per year, more than cancer [7]. 
Effective antibiotics are not only necessary to cure serious 
bacterial infections, they are also foundational to the modern 
medical establishment. Invasive medical procedures ranging 
from minor hip or knee surgeries to organ transplantations 
are performed safely and routinely thanks to the use of 
prophylactic antibiotics that limit the risk of post-operative 
infection. Antibiotics are also often used by people receiving 
treatment with chemotherapeutic or immunosuppressing 
drugs, both of which can leave an individual prone to bacterial 
infection. Given the role antibiotics play as a cornerstone of 
modern medicine, the threat of resistance cannot be ignored.
The ability for bacteria to become resistant to antibiotics is 
in fact a completely natural evolutionary response to our use 
of antibiotics in medicine and agriculture. It is important 
to realize that for as long as bacteria and other organisms 
have produced antibiotics, resistance to these compounds 
has also circulated in the environment. This is most clearly 
understood from the perspective of a bacterium that produces 
an antibiotic to give itself a competitive advantage in its 
environment. Clearly, the producing strain must be able to 
resist the antibiotic it produces itself, otherwise it wouldn’t 
survive very long. While genes that encode for antibiotic 
resistance are generally guarded by the strains that use them, a 
process known as gene transfer can lead to otherwise sensitive 
strains acquiring new resistance mechanisms. Another 
driver of antibiotic resistance is due to the process of genetic 
mutation. Mutations in the genes of a bacteria species occur 
spontaneously at a rate of about one in ten million. A bacterial 
infection represents a population of billions and billions of 
single celled bacteria. Due to spontaneous mutation there 
will always be a few cells that differ slightly from the others. 
While such mutations are rare and often do not provide an 
advantage to the mutant cell, in some cases they can allow a 
bacterium to resist the effect of an antibiotic. For example, a 
mutation that changes the structure of a bacterial protein that 
is targeted by an antibiotic can significantly reduce the effect 
of the antibiotic. Such a mutation will initially only impart 
a small number of bacteria with this advantage while the 
vast majority of the others remain sensitive to the antibiotic. 
Bacteria, however, reproduce at an amazing rate, in some cases 
doubling their population within 20 minutes. This means that 
an initially small subpopulation of mutant bacteria, can over 
a period hours become the dominant player in an antibiotic 
resistant infection. 
The process of acquired antibiotic resistance and the threat it 
posed was in fact observed and described by Fleming himself 
in his 1945 Nobel lecture. Fleming then stated:
“It is not difficult to make microbes resistant to penicillin in the 
laboratory by exposing them to concentrations not sufficient 
to kill them, and the same thing has occasionally happened in 
the body. The time may come when penicillin can be bought by 
anyone in the shops. Then there is the danger that the ignorant 
man may easily underdose himself and by exposing his microbes 
to non-lethal quantities of the drug make them resistant.”
It is a commonly held view that microorganisms use 
antibiotics and resistance genes as weapons and defenses 
against their bacterial competitors. More likely, however, is that 
in nature, antibiotics serve as signaling molecules, allowing 
for the establishment of harmonious microbial communities 
rich in bacterial diversity [8]. It is more likely that our 
“weaponizing” of antibiotics in the fight against infectious 
disease is responsible for the rapid and unpredictable rise in 
resistance.
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The impact of our industrialized use of antibiotics has created 
the exact scenario Fleming warned against. Nature was using 
antibiotics for her own means well before modern humans 
appeared on earth. It is the scale of our global antibiotic 
production and application that is now driving the widespread 
and increasing wave of resistance. Each year antibiotics are 
globally produced and consumed on the multi-ton scale. This 
has led to an inevitable and dramatic increase in the quantities 
of antibiotics that we now find in the environment [9]. Regular 
exposure to sub-lethal concentrations of antibiotics in waste 
streams and other environmental pools provides bacteria 
with precisely the conditions for resistance development that 
Fleming warned against.
While our use of antibiotics is vital to maintaining effective 
health care, it has also led us into uncharted territory as 
a species. We are currently in the midst of a massive, real 
time biological experiment. Over the past decades we have 
presented the planet’s pathogenic bacteria with an enormous 
evolutionary pressure to adapt to the antibiotics we use to 
keep them at bay. Since the golden age of the mid 20th century, 
we have injected more than a megaton of antibiotics into our 
environment [10]. How resistance rates will increase in the 
decades to come may not be simple to predict but the need for 
action is clear. 
So how do we address the threat posed by antibiotics 
resistance? One approach is to reduce our use of antibiotics, 
so called stewardship, an approach that can slow the rate at 
which resistance appears. It is clear, however, that we cannot 
completely eliminate our use of antibiotics and that effective 
antibacterial therapies will continue to be a cornerstone of our 
medical system. Today there is growing interest in alternative 
technologies for the treatment of bacterial infections. You 
might have heard of phage therapy, an intriguing approach to 
clearing infections with small viruses that specifically target 
bacterial cells. There are also efforts to develop so-called 
“biologic drugs” based on large antibody molecules that can 
selectively target bacterial cells. While both phage therapy and 
biologic drugs are very promising, there remains much work 
to do to demonstrate their widespread applicability. In the 
meantime, we should not ignore the amazing historic success 
of antibiotic drugs based on naturally occurring small organic 
molecules. 
During the golden age of antibiotic discovery, the “low hanging 
fruit” was plucked: those naturally occurring antibiotics 
that were found to be potent, effective, and safe for use in 
humans rapidly made their way to the clinic. Along the way 
however, many other classes of antibiotic compounds were 
also discovered that, while effective at killing bacteria in a 
petri dish, were not safe or effective in the human body. In 
the golden age such compounds were logically cast aside. 
Today, however, some researchers are returning to these 
molecular castaways as possible leads for the development of 
new antibiotic classes. This approach is part of the strategy 
that my research group uses in the hunt for new antibiotics by 
using organic chemistry-based strategies to address antibiotic 
resistance.
Addressing Antibiotic Resistance
One of the main themes in my group’s research is the use of 
organic chemistry to structurally modify natural product 
antibiotics to enhance their activity and safety. This technique 
is commonly referred to as “semi-synthesis”. In this approach 
we rely on Nature’s ability to generate structurally complex, 
biologically active molecules and then use organic chemistry 
to enhance their properties. But what, exactly, do I mean when 
I say we can enhance the properties of a naturally occurring 
antibiotic?
Well, some of the antibiotic molecules that nature produces 
are very potent and effective in their native environments but 
in our body are rapidly digested and/or excreted. The human 
body is very well equipped to remove foreign compounds. An 
early study conducted by the first PhD student in my group 
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Timo Koopmans, working in collaboration with colleague 
Eefjan Breukink, demonstrated that the naturally occurring 
antibiotic nisin could be modified to generate analogues that 
are much more stable to degradation and excretion [11]. These 
findings garnered much interest from the community and 
inspired us to pursue similar strategies with other classes of 
antibiotics.
In some cases, enhancing an antibiotic can mean reducing 
its toxicity. In a more recent and not yet published study, 
Jaco Slingerland has shown that structural modifications can 
significantly reduce the toxicity of the polymyxin class of 
antibiotics. The polymyxins are very important antibiotics 
because they are among the few options that doctors still have 
when treating certain multi-drug resistant infections. The 
drawback to the polymyxins is their high kidney toxicity. Our 
new semisynthetic polymyxins may circumvent this problem.
Yet a third approach to enhancing a naturally occurring 
antibiotic is by modifying its structure in a way that enables 
it to overcome resistance. To this end we recently undertook 
studies aimed at modifying the structure of vancomycin, 
one of the most important antibiotics used in hospitals 
around the world. Unfortunately, vancomycin resistance is 
rapidly increasing and for some bacterial species vancomcyin 
resistance is now more common than not. To address this 
issue recent work by Emma van Groesen, has revealed that 
certain structural modifications can dramatically increase the 
activity of vancomycin towards resistant strains – in some 
cases by many thousands fold. Ongoing studies are aimed at 
establishing how well these new vancomycin variants work in 
treating infections in vivo. 
Aside from modifying complex natural molecules by semi-
synthesis, my group has also undertaken the total synthesis 
of various antibiotics. In some cases it is easier to completely 
synthesize a molecule than try to isolate it from natural 
sources. Total synthesis also offers a much broader range 
of possibilities for the generation of unnatural structural 
analogues. Most notable in this line of research is the work 
we’ve carried out on the family of calcium-dependent 
antibiotics. These antibiotics present promising leads for 
clinical development but many questions remain about how 
they actually kill bacteria. Early efforts in our group by Peter 
‘t Hart demonstrated the feasibility of preparing calcium-
dependent antibiotics by total synthesis [12]. This work 
was subsequently elaborated upon by Laurens Kleijn who, 
in collaboration with the group of Bert Janssen, succeeded 
in obtaining a crystal structure of the calcium-dependent 
antibiotic Laspartomycin C in complex with its bacterial target 
[13, 14]. This seminal work represents the first crystal structure 
of such an antibiotic bound to its bacterial target and provides 
key mechanistic insight. Ongoing efforts by Tom Wood and 
Karol Al Ayed are currently aimed at further elucidating the 
structure-activity relationships for Laspartomycin C and other 
members of this unique class of antibiotics.
The examples of our research that I’ve described so far are 
concerned with understanding and improving the properties 
of antibiotics by structural modification. There is, however, 
another approach one can take in trying to overcome 
drug-resistant bacteria: by interfering with the resistance 
mechanisms themselves. Some bacterial strains called Gram-
negatives have an extra outer membrane that can prevent 
antibiotics from entering the cell. In this way Gram-negative 
bacteria are inherently resistant to many antibiotics. Current 
work in our group carried out by Charlotte Wesseling, in 
collaboration with the group of Suzan Rooijakkers, is aimed 
at developing compounds that can disrupt the Gram-negative 
outer membrane as a means of sensitizing them to antibiotics. 
In another approach we are also working to target acquired 
resistance mechanisms where bacteria use specific enzymes to 
actively destroy antibiotics. Investigations initiated by Kamal 
Tehrani and Matthijs van Haren, and recently followed up by 
Nicola Wade and Ioli Kotsogianni, have led to the development 
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of a new class of small molecule inhibitors that blocks the 
activity of an especially dangerous family of resistance 
enzymes. Our in vitro studies reveal that when combined with 
one of our new inhibitors, conventional antibiotics are once 
again able to kill resistant bacteria. These findings are the basis 
of a patent application that we recently filed with the Leiden 
University Technology Transfer Office. In the coming months 
we will carry out the first in vivo studies with these new 
inhibitors. Exciting times!
As I hope I’ve illustrated with these examples from my own 
group’s work, I am optimistic that a dedicated, global research 
effort can effectively address the problem of antibiotic 
resistance. Yes, the low hanging fruit was plucked long ago but 
today we have new insights and technologies to help in the 
fight. Furthermore, it is also to our advantage that bacterial 
cells are so different from the cells in our body. When trying to 
treat diseases like cancer it can be very difficult to distinguish 
diseased cells from healthy cells. Bacterial cells on the other 
hand offer many unique targets and metabolic processes that 
the cells in our body do not employ. In addition, the resistance 
mechanisms that bacteria develop in response to antibiotic 
pressure can also present an opportunity for the development 
of new therapeutic strategies. As the famous Dutch 
philosopher Hendrik Johannes Cruijff once said, “Elk nadeel 
heb zijn voordeel”. If we closely monitor the emergence of new 
resistance mechanisms, and understand them at the molecular 
level, we may also be able to exploit them. 
The simple fact of the matter is that our use of antibiotics will 
continue to drive resistance. This is unavoidable and places us 
in an arms race of sorts where we find ourselves pitted against 
a highly adaptable bacterial foe. 
The Future of Antibiotic Development
While I am confident about the scientific community’s 
capacity to innovate in response to the threat of antibiotic 
resistance, current economic realities provide less reason for 
optimism. Simply put, with the “low hanging fruit” already 
plucked, antibiotics currently present a very poor business 
case. Today, it costs about the same number of dollars to 
develop a new antibiotic as it does to develop a new medicine 
for any other disease. The problem is that antibiotics tend to 
earn much less money compared to drugs for other disease 
areas [15]. 
As for any new drug, a company that brings a new antibiotic 
to market hopes to recoup the costs invested in developing 
the new medicine as well as the costs sunk on the inevitable 
failures along the way, remember the “one in ten thousand” 
number. While drugs for cancer and autoimmune diseases, 
which are taken for extended periods, if not for life, are very 
expensive, antibiotics are cheap and typically only require a 
week to ten days to cure a patient’s infection. Furthermore, 
the likelihood of resistance development to any new antibiotic 
provides additional disincentive for drug makers.
As a class of drugs antibiotics present a perplexing paradox. 
When they work, antibiotics are the best deal in health care for 
patients: they are low cost, safe medicines that generally offer a 
complete cure in just days. On the other hand, antibiotics are 
no longer profitable enough for companies to justify working 
on. In 1980 there were twenty-five large pharmaceutical 
companies with active antibiotic discovery programs 
worldwide, today there are three.
So what can be done? While it’s tempting to wag one’s finger at 
drug companies for not solving the problem, this will not lead 
to change. Drug companies, like any other businesses, exist to 
produce products that will keep them in business. Antibiotics 
simply do not represent such a product in the current 
marketplace. This is a clear case of market failure and requires 
a different approach. 
Today there is a growing appreciation for the foundational 
role that antibiotics play in our health care system. This view 
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of “antibiotics as infrastructure” is spurring discussions about 
new economic models that might give companies a reason 
to once again consider antibiotic development as a viable 
business model [16]. In July 2019 the UK’s National Health 
Service announced a novel compensation scheme wherein 
companies will be paid a “license fee” for providing access to 
a new antibiotic. This subscription style model will see drug 
companies paid upfront for their new antibiotics, regardless of 
the number of prescriptions written by doctors. The American 
government is also reviewing similar proposals designed to 
provide incentives for drug developers to once again turn their 
gaze towards antibiotic development.
I would also like to take a moment to address the potential 
role that academic researchers might play in delivering the 
antibiotic of the future. Increasingly we as researchers are 
being asked to communicate the societal relevance of our 
work. Anyone who has submitted an NWO grant in recent 
years is no doubt familiar with the “Utilization Potential” 
section. Most of us will agree that the Academy is, and should 
remain, the home of fundamental, curiosity-driven research. 
That said, it can also be a place where focused, goal-oriented 
work is conducted. While not every academic research line will 
lead to patents and new medicines, those that might should be 
provided the chance to make an impact beyond the walls of the 
university. 
The Leiden BioScience Park is one of the top science parks 
in Europe and presents a unique ecosystem for university 
researchers looking to create innovative spin out companies 
based on their academic findings. If encouraged and 
properly supported, such activities can deliver great benefit 
to researchers, the university, and society. I very much look 
forward to working with members of the science faculty 
and executive board in creating opportunities to realize the 
translational potential of the research conducted at this fine 
University where I am honored to accept the title of Professor 
today.
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